|
WO2008009125A1
|
|
Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
|
|
US2007184554A1
|
|
Biomarker of improved intestinal function
|
|
WO2005046798A1
|
|
Treatment of bone loss utilizing full length parathyroid hormone
|
|
US2005032698A1
|
|
Stabilized formulation of parathyroid hormone
|
|
US2004152740A1
|
|
Arylglycine derivatives for use as glycine transport inhibitors
|
|
US2004152741A1
|
|
Arylglycine derivatives and their use as glycine transport inhibitors
|
|
EP1572720A2
|
|
Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
|
|
HK1050142A1
|
|
Glp-2 formulations
|
|
AU6556601A
|
|
Glucagon-like peptide-2 analogs
|
|
AU5454601A
|
|
Aminopiperidines
|
|
US6897215B1
|
|
Compounds having 5-HT6 receptor antagonist activity
|
|
WO0132660A1
|
|
Compounds having 5-ht6 receptor antagonist activity
|
|
MXPA02004354A
|
|
Diaryl enynes.
|
|
US6426364B1
|
|
Diaryl-enynes
|
|
AU6310300A
|
|
Azaindoles having serotonin receptor affinity
|
|
US6686374B1
|
|
Azaindoles having serotonin receptor affinity
|
|
CA2378047A1
|
|
Heterocyclic compounds for the treatment of migraine
|
|
AU2899900A
|
|
Cloned human sphingosine kinase homologues
|
|
GB0000031D0
|
|
GLP-2 formulations
|
|
GB9930882D0
|
|
GLP-2 formulations
|
